.png)
Total amount raised
$107M
Latest funding date
2025-05-09
Location
Redox has successfully raised funding through nine rounds, with the latest being a convertible note. The company has attracted a total of 13 investors, including notable names like Dreamit Ventures and RRE Ventures.
Keep reading to explore the intricacies of Redox's fundraising journey and the investors backing this innovative healthcare data integration platform.
Redox has raised funding across nine rounds, backed by 13 investors including Adams Street Partners, Battery Ventures, RRE Ventures, and .406 Ventures.
Keep reading to explore Redox's fundraising journey, from its 2014 seed round to its most recent convertible note in 2025.
What Is Redox?
Redox is a healthcare data interoperability company headquartered in Madison, Wisconsin. Founded in 2014, Redox operates a platform that enables organizations to send, receive, process, and act on real-time healthcare data from any source. The platform supports over 12,200 connected healthcare organizations, 14,900+ live integrations, and more than 100 EHR connections. Redox is HITRUST r2 certified and SOC 2® Type 2 compliant, and has processed over 109 billion healthcare messages since its founding.
How Much Funding Has Redox Raised?
- Seed Round
- Amount Raised: USD 470,000
- Date: November 2014
- Lead Investors: Not publicly disclosed
- Participants: Not publicly disclosed
- Series A
- Amount Raised: USD 3,530,000
- Date: October 2015
- Lead Investors: .406 Ventures
- Participants: Flybridge Capital Partners, HealthX Ventures
- Non-Equity Assistance
- Amount Raised: Undisclosed
- Date: December 2016
- Lead Investors: Not publicly disclosed
- Series B
- Amount Raised: USD 9,000,000
- Date: January 2017
- Lead Investors: RRE Ventures
- Participants: .406 Ventures, HealthX Ventures, Flybridge Capital Partners
- Series B (Extension)
- Amount Raised: USD 1,000,000
- Date: April 2017
- Lead Investors: Intermountain Healthcare Innovation Fund
- Debt Financing
- Amount Raised: USD 3,000,000
- Date: August 2018
- Lead Investors: Not publicly disclosed
- Series C
- Amount Raised: USD 33,000,000
- Date: April 2019
- Lead Investors: Battery Ventures
- Participants: .406 Ventures, RRE Ventures, Intermountain Ventures
- Series D
- Amount Raised: USD 45,000,000
- Date: February 2021
- Lead Investors: Adams Street Partners
- Participants: Avenir, Battery Ventures, .406 Ventures, RRE Ventures
- Convertible Note
- Amount Raised: USD 12,281,727
- Date: May 2025
- Lead Investors: Not publicly disclosed
Total Amount Raised: At least USD 107,281,727 based on disclosed funding.
Key Investors
- Adams Street Partners
- Details: Adams Street Partners is a global private equity firm that led Redox's $45M Series D round in February 2021. Thomas Bremner represented the firm in the investment.
- Battery Ventures
- Details: Battery Ventures led Redox's $33M Series C round in April 2019. Chelsea Stoner represented the firm and also participated in the Series D round.
- RRE Ventures
- Details: RRE Ventures led Redox's $9M Series B round in January 2017. General partner Raju Rishi joined the Redox board of directors. RRE also participated in Series C and Series D rounds.
- .406 Ventures
- Details: .406 Ventures led Redox's $3.5M Series A round in October 2015 and continued as a participant through Series B, Series C, and Series D rounds.
- Avenir
- Details: Avenir participated as an investor in Redox's Series D round in February 2021.
- Flybridge Capital Partners
- Details: Flybridge Capital Partners participated in Redox's Series A (October 2015) and Series B (January 2017) rounds.
- HealthX Ventures
- Details: HealthX Ventures participated in Redox's Series A (October 2015) and Series B (January 2017) rounds.
- Intermountain Healthcare Innovation Fund
- Details: Intermountain Healthcare provided $1M in strategic follow-on investment as part of the Series B extension in April 2017. Intermountain Ventures also participated in the Series C round.
- Dreamit Ventures
- Details: Dreamit Ventures is listed as an investor in Redox per Crunchbase, with partners Darren Sandberg and Mel Shakir identified.
What's Next for Redox?
Redox is positioned to continue its growth as a leading healthcare interoperability platform. With its latest convertible note in May 2025, the company is likely deploying capital toward product innovation, expanding its network of connected healthcare organizations, and strengthening its data exchange capabilities. Given the ongoing push for healthcare data standardization and the growth of FHIR-based interoperability mandates, Redox is well-positioned to capture increasing demand for seamless EHR integrations across vendors, providers, payers, and life sciences organizations.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data. Sign up for free today.
